Company file · TECH

Bio-Techne

Bio-Techne's revenue fell 0.4% in FY2026, to $1.2B, and net income rose 147.8% to $182M

Revenue fell 0.4% to $1.2B in FY2026, from $1.2B in FY2025. Net income rose 147.8% to $182M. Protein Sciences was the largest segment, at 72% of revenue.

Prepared from SEC filings · Latest annual report: 10-K for FY2026 (filed Aug 24, 2026) · Latest quarter: 10-Q for the quarter ended Sep 30, 2026 (filed Nov 6, 2026) · Data pulled Nov 11, 2026

Key facts

In fiscal 2026, which ended Jun 30, 2026, Bio-Techne (Nasdaq: TECH) took in $1.2B of revenue (down 0.4% on fiscal 2025); net income was $182M (up 147.8%). The most recent quarter, ended Sep 30, 2026, brought revenue of $300M, up 4.6% year over year, with net income of $28M. Protein Sciences was the biggest single line by segment: 72% of fiscal 2026 revenue. Sources: 10-K for fiscal 2026 (filed Aug 24, 2026) and 10-Q for the quarter ended Sep 30, 2026 (filed Nov 6, 2026).

Revenue$1.2BFY2026 · −0.4% vs FY2025

Net income$182MFY2026 · +147.8% vs FY2025

Operating cash flow$292MFY2026 · +1.6% vs FY2025

Cash & equivalents$350Mat Sep 30, 2026 · +32.2% vs FY2026 end

Total debt$200MFY2026 end · −42.2% vs FY2025

Diluted shares157MFY2026 avg · −1.7% vs FY2025

Revenue and net income, three fiscal yearsBy fiscal year, $bn

RevenueNet income

Source: 10-K FY2026, filed Aug 24, 2026

Quarterly revenue: fiscal 2027 vs a year earlierFiscal Q1, $bn (each quarter from that quarter's 10-Q)

FY2026FY2027

Source: 10-Q filed Nov 6, 2026

How it makes money

By segment, FY2026

LineAmountSharevs FY2025
Protein Sciences$875M72%+0.5%
Diagnostics and Spatial Biology$336M28%−2.9%

Source: 10-K FY2026, XBRL breakdown

By segment in FY2026: Protein Sciences (72%) and Diagnostics and Spatial Biology (28%), as shares of total revenue. Total revenue was $1.2B.

By segment: three-year mixShare of the total each fiscal year

FY2024

72%28%

FY2025

72%28%

FY2026

72%28%

Protein SciencesDiagnostics and Spatial Biology

Source: 10-K FY2026

By product or service, FY2026

Product and Services$1.2B98%−0.5%

Royalty$25M2%+5.5%

Share is of the FY2026 total; the last column is the change from FY2025.

Learn more: Revenue vs. net income · Gross, operating and net margin

What changed last quarter

How the quarter compared with a year earlier

Comparing Q1 FY2027 (Jul to Sep 2026) compared with Q1 FY2026 (Jul to Sep 2025)

Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.

Q1 FY2027Q1 FY2026

Company

Revenue

$300M Q1 FY2027

$287M Q1 FY2026

4.6% increase

Net income

$28M Q1 FY2027

$38M Q1 FY2026

25.9% decrease

Source: Bio-Techne 10-Q for the quarter ended Sep 30, 2026, filed Nov 6, 2026

By segment

Protein Sciences

$220M Q1 FY2027

$202M Q1 FY2026

8.7% increase

Diagnostics and Spatial Biology

$80M Q1 FY2027

$79M Q1 FY2026

0.9% increase

Source: Bio-Techne 10-Q for the quarter ended Sep 30, 2026, filed Nov 6, 2026

Cash & equivalents $350M at Sep 30, 2026, vs $265M at FY2026 end.
Operating cash flow, first 3 months of fiscal 2027: $73M vs $28M a year earlier.

The bull case and the bear case

The bull case

Net income rose 147.8% in FY2026 to $182M, from $73M. 10-K, FY2026
Operating cash flow rose 1.6% in FY2026 to $292M. 10-K, FY2026
Diluted shares fell 1.7% in FY2026, so each share represents a larger slice of profit. 10-K, FY2026
Total debt fell 42.2% in FY2026 to $200M. 10-K, FY2026

The bear case

Revenue fell 0.4% in FY2026 to $1.2B, from $1.2B a year earlier. 10-K, FY2026
Net income in the quarter ended Sep 30, 2026 was $28M, down 25.9% on a year earlier. 10-Q, quarter ended Sep 30, 2026
Diagnostics and Spatial Biology revenue fell 2.9% in FY2026 to $336M. 10-K, FY2026
Product and Services revenue fell 0.5% in FY2026 to $1.2B. 10-K, FY2026

What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.

What the company does

Bio-Techne is in the life sciences tools & services industry, part of the health care sector. The SEC files it under Biological Products, (No Diagnostic Substances).

Bio-Techne reports 2 segments: Protein Sciences and Diagnostics and Spatial Biology.

Its fiscal year ends in June; the latest, FY2026, ended Jun 30, 2026.

Source: 10-K, Item 1 Business

Risks common in this industry

These are general risks for companies in the life sciences tools & services industry. They are not a summary of Bio-Techne’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.

RegulationApprovals, safety rules and government oversight shape what it can sell and how.
Pricing and reimbursementPayers, insurers and governments influence what it can charge.
CompetitionNew treatments, generics and rival products can take share.
LitigationProduct liability and other legal claims can lead to costs.
SupplyManufacturing and supplier problems can interrupt products.

Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)

Three years of key numbers

Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.

US$	FY2024	FY2025	FY2026
Revenue	$1.2B	$1.2B	$1.2B
Net income	$168M	$73M	$182M
Operating cash flow	$299M	$288M	$292M
Cash & equivalents (year end)	$152M	$162M	$265M
Total debt (year end)	$319M	$346M	$200M
Diluted shares	161M	160M	157M

Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
Net income: Net income including the share that belongs to minority owners of subsidiaries.
Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
Total debt: Long-term debt, at carrying value.
Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.

Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator

Explainers for this page

Plain-English guides to terms this file uses, with real numbers from filings.

About these numbers

Bio-Techne names its fiscal year by the calendar year in which it ends, so FY2026 is the year that ended Jun 30, 2026.
Net income here includes the share that belongs to minority owners of subsidiaries, the figure the company's tagged data carries for the whole business.

Recent filings

Form	Filed	Period
10-Q	Nov 6, 2026	Sep 30, 2026
10-K	Aug 24, 2026	Jun 30, 2026

Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters

Common questions about Bio-Techne

How does Bio-Techne make money?

In fiscal 2026, revenue totaled $1.2B. By segment in FY2026: Protein Sciences (72%) and Diagnostics and Spatial Biology (28%), as shares of total revenue. Total revenue was $1.2B. Source: 10-K for fiscal 2026, filed Aug 24, 2026.

What was Bio-Techne's revenue in fiscal 2026?

Revenue came to $1.2B in the year ended Jun 30, 2026. Going back two years, it was $1.2B in fiscal 2024 and $1.2B in fiscal 2025, so the latest year was down 0.4%. Source: 10-K for fiscal 2026, filed Aug 24, 2026.

Is Bio-Techne profitable?

Yes, by US accounting rules (GAAP): net income was $182M in fiscal 2026, up 147.8% from $73M a year earlier. For the quarter ended Sep 30, 2026, net income was $28M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2026, filed Aug 24, 2026.

What did Bio-Techne report in its latest quarterly filing?

The 10-Q for the quarter ended Sep 30, 2026 shows revenue of $300M, against $287M in the same quarter a year before (up 4.6%), and net income of $28M, against $38M (down 25.9%). Source: 10-Q for the quarter ended Sep 30, 2026, filed Nov 6, 2026.

What are the main risks Bio-Techne faces?

Bio-Techne's own risk factors are in Item 1A of its 10-K for fiscal 2026, filed Aug 24, 2026. Risks that are common among companies in the life sciences tools & services industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.

Where do these Bio-Techne numbers come from?

Two filings Bio-Techne made with the SEC: its fiscal 2026 10-K, filed Aug 24, 2026, and its 10-Q for the quarter ended Sep 30, 2026, filed Nov 6, 2026. The figures are taken from the XBRL data the SEC publishes, and every one links back to its source. Methodology explains how fiscal years and missing numbers are handled.

Tracked funds that report owning Bio-Techne

Ruane Cunniff & Goldfarb: 3,348,841 shares, reported value $236.6M at Jun 30, 2026 (−1.3% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Maverick Capital: 1,535,610 shares, reported value $108.5M at Jun 30, 2026 (−67.6% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Millennium Management: 989,033 shares, reported value $69.9M at Jun 30, 2026 (new in this filing). Form 13F filed Aug 14, 2026.
Citadel Advisors: 965,918 shares, reported value $68.2M at Jun 30, 2026 (+2,125.5% in shares since the filing for Mar 31, 2026). Form 13F filed Sep 2, 2026.
Soros Fund Management: 535,400 shares, reported value $37.8M at Jun 30, 2026 (new in this filing). Form 13F filed Aug 14, 2026.
Durable Capital Partners: 501,963 shares, reported value $35.5M at Jun 30, 2026 (−88.7% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Two Sigma Investments: 69,625 shares, reported value $4.9M at Jun 30, 2026 (+5.3% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
Bridgewater Associates: 26,750 shares, reported value $1.9M at Jun 30, 2026 (+347.5% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.

From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.

Disclosures

Editor holdings in TECH: The editor holds no position in Bio-Techne (TECH). As of Nov 11, 2026.
Trading rule: The editor does not buy or sell TECH from 3 days before to 3 days after this page is published or substantively updated.
Compensation: Nobody paid for this page. No affiliate links on this page.
Sources: The company's SEC filings, linked next to each number or, for charts, in the source line under them.
Last updated: Nov 10, 2026

General education, the same for every reader. Not a recommendation to buy, sell or hold TECH, and it doesn't consider your situation.

Compare with peers

Company	Fiscal year	Revenue	Revenue growth	Net income
Bio-TechneTECH	FY2026	$1.2B	−0.4%	$182M
Thermo FisherTMO	FY2025	$44.6B	+3.9%	$6.7B
DanaherDHR	FY2025	$24.6B	+2.9%	$3.6B
Agilent TechnologiesA	FY2025	$6.9B	+6.7%	$1.3B
WatersWAT	FY2025	$3.2B	+7.0%	$643M

Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.

More company files

New to filings? Learn has plain-English explainers and Tools has calculators. Methodology & Disclosures covers where every number comes from.